Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03937219
Title Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Exelixis
Indications

clear cell renal cell carcinoma

Therapies

Cabozantinib + Nivolumab

Ipilimumab + Nivolumab

Cabozantinib + Ipilimumab + Nivolumab

Age Groups: senior | adult
Covered Countries USA | CAN


No variant requirements are available.